S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   386.81 (-1.78%)
AAPL   164.60 (-0.42%)
MSFT   330.19 (-0.12%)
FB   311.25 (-4.07%)
GOOGL   2,825.22 (-0.45%)
AMZN   3,448.00 (-1.68%)
TSLA   1,088.89 (-4.88%)
NVDA   314.80 (-3.66%)
BABA   122.75 (-3.75%)
NIO   38.35 (-1.99%)
CGC   9.94 (-7.19%)
AMD   149.12 (-5.84%)
GE   93.23 (-1.85%)
MU   85.20 (+1.43%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.12 (-1.92%)
PFE   54.78 (+1.95%)
AMC   29.98 (-11.67%)
ACB   6.01 (-6.39%)
BA   187.95 (-5.00%)
NASDAQ:KLDO

Kaleido Biosciences Stock Forecast, Price & News

$3.42
-0.17 (-4.74%)
(As of 12/1/2021 03:59 PM ET)
Add
Compare
Today's Range
$3.35
▼
$3.67
50-Day Range
$3.59
▼
$6.02
52-Week Range
$3.35
▼
$20.50
Volume
2,091 shs
Average Volume
241,146 shs
Market Capitalization
$145.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.33
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Kaleido Biosciences logo

About Kaleido Biosciences

Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.

Headlines

Global IoT Roaming Data Traffic to Reach 650pb in 2026, Despite Supply Chain Concerns: Kaleido Intelligence
November 24, 2021 |  businesswire.com
Kaleido Biosciences, Inc. (NASDAQ:KLDO) Given Average Rating of "Buy" by Brokerages
November 16, 2021 |  americanbankingnews.com
Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021 |  finance.yahoo.com
Kaleido Biosciences (NASDAQ:KLDO) Price Target Cut to $11.00
November 12, 2021 |  americanbankingnews.com
Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer
November 10, 2021 |  finance.yahoo.com
Here's Why Kaleido Biosciences, Inc. (KLDO) Is a Great 'Buy the Bottom' Stock Now
November 1, 2021 |  finance.yahoo.com
Kaleido Biosciences Reports Third Quarter 2021 Financial Results
November 1, 2021 |  finance.yahoo.com
Kaleido Biosciences, Inc. (KLDO) Reports Q3 Loss, Misses Revenue Estimates
November 1, 2021 |  finance.yahoo.com
Down 23.6% in 4 Weeks, Here's Why Kaleido Biosciences, Inc. (KLDO) Looks Ripe for a Turnaround
October 28, 2021 |  finance.yahoo.com
Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
October 25, 2021 |  finance.yahoo.com
Kaleido Biosciences Shares Drop 11% After Topline Data for Ulcerative Colitis Treatment
October 6, 2021 |  marketwatch.com
Why Did Kaleido Shares Plunge 10% On Tuesday?
October 6, 2021 |  msn.com
Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis
October 5, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KLDO
Previous Symbol
CUSIP
N/A
CIK
1751299
Web
www.kaleido.com
Phone
(617) 674-9000
Fax
N/A
Employees
82
Year Founded
N/A

Sales & Book Value

Annual Sales
$980 thousand
Price / Sales
148.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
42,594,000
Free Float
38,761,000
Market Cap
$145.67 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/01/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/02/2022

MarketRank™

Overall MarketRank™

1.89 out of 5 stars

Medical Sector

726th out of 1,392 stocks

Analyst Opinion: 3.3Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

Is Kaleido Biosciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kaleido Biosciences stock.
View analyst ratings for Kaleido Biosciences or view top-rated stocks.

How has Kaleido Biosciences' stock price been impacted by COVID-19?

Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KLDO shares have decreased by 38.3% and is now trading at $3.42.
View which stocks have been most impacted by COVID-19.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Kaleido Biosciences.

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) released its quarterly earnings results on Monday, November, 1st. The company reported ($0.54) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.54). The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.25 million.
View Kaleido Biosciences' earnings history.

What price target have analysts set for KLDO?

5 brokers have issued twelve-month price objectives for Kaleido Biosciences' shares. Their forecasts range from $3.00 to $22.00. On average, they expect Kaleido Biosciences' stock price to reach $14.80 in the next twelve months. This suggests a possible upside of 332.7% from the stock's current price.
View analysts' price targets for Kaleido Biosciences or view top-rated stocks among Wall Street analysts.

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the following people:
  • Daniel L. Menichella, President, Chief Executive Officer & Director
  • Jerald Korn, Chief Operating Officer & General Counsel
  • William E. Duke, Chief Financial Officer
  • Johan van Hylckama Vlieg, Chief Scientific Officer
  • Kimberly Hocknell, Senior Vice President-Technical Operations

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Who are Kaleido Biosciences' major shareholders?

Kaleido Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.58%), Geode Capital Management LLC (0.88%), Bank of New York Mellon Corp (0.19%), Goldman Sachs Group Inc. (0.09%), State Board of Administration of Florida Retirement System (0.08%) and Morgan Stanley (0.08%). Company insiders that own Kaleido Biosciences stock include Kyriazi Theo Melas and Ventures Fund Iv Gene Flagship.
View institutional ownership trends for Kaleido Biosciences.

Which major investors are selling Kaleido Biosciences stock?

KLDO stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, SG Americas Securities LLC, California State Teachers Retirement System, Morgan Stanley, and Cerity Partners LLC.
View insider buying and selling activity for Kaleido Biosciences or view top insider-selling stocks.

Which major investors are buying Kaleido Biosciences stock?

KLDO stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, State Board of Administration of Florida Retirement System, Bank of New York Mellon Corp, BlackRock Inc., Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Close Asset Management Ltd, and Barclays PLC. Company insiders that have bought Kaleido Biosciences stock in the last two years include Kyriazi Theo Melas, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Kaleido Biosciences or or view top insider-buying stocks.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $3.42.

How much money does Kaleido Biosciences make?

Kaleido Biosciences has a market capitalization of $145.67 million and generates $980 thousand in revenue each year.

How many employees does Kaleido Biosciences have?

Kaleido Biosciences employs 82 workers across the globe.

What is Kaleido Biosciences' official website?

The official website for Kaleido Biosciences is www.kaleido.com.

How can I contact Kaleido Biosciences?

The company can be reached via phone at (617) 674-9000.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.